Diagnosis of rapidly progressive dementia (RPD) poses a complex medical challenge that requires an exhaustive evaluation. Although prion diseases, in particular Creutzfeldt-Jakob disease (CJD), are often suspected, many other nonprion diseases may present as RPD. Our aim was to review the causes of RPD in our center to better understand the underlying conditions. We reviewed clinical, neuroimaging, and cerebrospinal fluid data from patients with RPD admitted to our hospital from 1994 to 2009. Forty-nine patients (mean age at onset 72.4 y) with RPD were admitted to our center during the study period. The mean interval between the onset of symptoms and admission was 4.6 months. The final clinical diagnoses were as follows: nonprion neurodegenerative diseases (36.8%), CJD (30.6%), vascular dementia (8.2%), toxic-metabolic conditions (8.2%), and other disorders (16.2%). Among cases with informed death (n = 19), the average survival time was 8.6 ± 9.5 months. Survival was shorter among patients with prion disease (n = 10) than in those with other diagnoses (n = 9, P = 0.004). In conclusion, nonprion neurodegenerative diseases are the most common cause of RPD in our center. Our results suggest that although CJD is often suspected as a cause of RPD, its frequency depends on the referral differences across specialized centers.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/WAD.0b013e3182368ed4 | DOI Listing |
Annu Rev Pathol
January 2025
MASLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, California, USA; email:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health problem, affecting ∼1 billion people. This condition is well established to have a heritable component with strong familial clustering. With the extraordinary breakthroughs in genetic research techniques coupled with their application to large-scale biobanks, the field of genetics in MASLD has expanded rapidly.
View Article and Find Full Text PDFEur J Trauma Emerg Surg
January 2025
Facultad de Medicina Humana, Universidad Privada Antenor Orrego, Trujillo, Perú.
Introduction: Sepsis is a systemic process that refers to a deregulated immune response of the host against an infectious agent, involving multiple organ dysfunction. It is rapidly progressive and has a dismal prognosis, with high mortality rates. For this reason, it is necessary to have a tool for early recognition of these patients, with the aim of treating them appropriately in a timely manner.
View Article and Find Full Text PDFBiosensors (Basel)
January 2025
Institute of Microelectronics and Optoelectronics, Warsaw University of Technology, Koszykowa 75, 00-662 Warsaw, Poland.
Surface Plasmon Resonance (SPR)-based biodetection systems have emerged as powerful tools for real-time, label-free biomolecular interaction analysis, revolutionizing fields such as diagnostics, drug discovery, and environmental monitoring. This review highlights the foundational principles of SPR, focusing on the interplay of evanescent waves and surface plasmons that underpin its high sensitivity and specificity. Recent advancements in SPR technology, including enhancements in sensor chip materials, integration with nanostructures, and coupling with complementary detection techniques, are discussed to showcase their role in improving analytical performance.
View Article and Find Full Text PDFBiosensors (Basel)
January 2025
College of Optical and Electronic Technology, China Jiliang University, Hangzhou 310018, China.
Nucleic acid aptamers are single-stranded oligonucleotides that are selected through exponential enrichment (SELEX) technology from synthetic DNA/RNA libraries. These aptamers can specifically recognize and bind to target molecules, serving as specific recognition elements. Surface-enhanced Raman scattering (SERS) spectroscopy is an ultra-sensitive, non-destructive analytical technique that can rapidly acquire the "fingerprint information" of the measured molecules.
View Article and Find Full Text PDFCurr Oncol
December 2024
School of Pharmacy, University of Waterloo, Waterloo, ON N2L 3G1, Canada.
The treatment landscape for patients with advanced ALK-positive NSCLC has rapidly evolved following the approval of several ALK TKIs in Canada. However, public funding of ALK TKIs is mostly limited to the first line treatment setting. Using linked provincial health administrative databases, we examined real-world outcomes of patients with advanced ALK-positive NSCLC receiving ALK TKIs in Ontario between 1 January 2012 and 31 December 2021.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!